Collegium Pharmaceutical (COLL) Added to Conviction List at Needham on Diversifying Revenue Base
Tweet Send to a Friend
Needham & Company analyst Serge Belanger reiterated a Buy rating and $34.00 price target on Collegium Pharmaceutical (NASDAQ: COLL) while ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
